144 related articles for article (PubMed ID: 31589047)
1. Protein Stability Effects in Aggregate-Based Enzyme Inhibition.
Torosyan H; Shoichet BK
J Med Chem; 2019 Nov; 62(21):9593-9599. PubMed ID: 31589047
[TBL] [Abstract][Full Text] [Related]
2. A specific mechanism of nonspecific inhibition.
McGovern SL; Helfand BT; Feng B; Shoichet BK
J Med Chem; 2003 Sep; 46(20):4265-72. PubMed ID: 13678405
[TBL] [Abstract][Full Text] [Related]
3. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams.
Wang X; Minasov G; Shoichet BK
Proteins; 2002 Apr; 47(1):86-96. PubMed ID: 11870868
[TBL] [Abstract][Full Text] [Related]
4. Promiscuous aggregate-based inhibitors promote enzyme unfolding.
Coan KE; Maltby DA; Burlingame AL; Shoichet BK
J Med Chem; 2009 Apr; 52(7):2067-75. PubMed ID: 19281222
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AmpC beta-lactamase through a destabilizing interaction in the active site.
Trehan I; Beadle BM; Shoichet BK
Biochemistry; 2001 Jul; 40(27):7992-9. PubMed ID: 11434768
[TBL] [Abstract][Full Text] [Related]
6. How Do Small Molecule Aggregates Inhibit Enzyme Activity? A Molecular Dynamics Study.
Ghattas MA; Al Rawashdeh S; Atatreh N; Bryce RA
J Chem Inf Model; 2020 Aug; 60(8):3901-3909. PubMed ID: 32628846
[TBL] [Abstract][Full Text] [Related]
7. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors.
Coan KE; Shoichet BK
J Am Chem Soc; 2008 Jul; 130(29):9606-12. PubMed ID: 18588298
[TBL] [Abstract][Full Text] [Related]
8. Functional analyses of AmpC beta-lactamase through differential stability.
Beadle BM; McGovern SL; Patera A; Shoichet BK
Protein Sci; 1999 Sep; 8(9):1816-24. PubMed ID: 10493583
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and thermodynamic consequences of the removal of the Cys-77-Cys-123 disulphide bond for the folding of TEM-1 beta-lactamase.
Vanhove M; Guillaume G; Ledent P; Richards JH; Pain RH; Frère JM
Biochem J; 1997 Jan; 321 ( Pt 2)(Pt 2):413-7. PubMed ID: 9020874
[TBL] [Abstract][Full Text] [Related]
10. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of beta-lactamases by monocyclic acyl phosph(on)ates.
Kaur K; Adediran SA; Lan MJ; Pratt RF
Biochemistry; 2003 Feb; 42(6):1529-36. PubMed ID: 12578365
[TBL] [Abstract][Full Text] [Related]
12. Stability and equilibria of promiscuous aggregates in high protein milieus.
Coan KE; Shoichet BK
Mol Biosyst; 2007 Mar; 3(3):208-13. PubMed ID: 17308667
[TBL] [Abstract][Full Text] [Related]
13. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
14. Stable Colloidal Drug Aggregates Catch and Release Active Enzymes.
McLaughlin CK; Duan D; Ganesh AN; Torosyan H; Shoichet BK; Shoichet MS
ACS Chem Biol; 2016 Apr; 11(4):992-1000. PubMed ID: 26741163
[TBL] [Abstract][Full Text] [Related]
15. Binding properties of a peptide derived from beta-lactamase inhibitory protein.
Rudgers GW; Huang W; Palzkill T
Antimicrob Agents Chemother; 2001 Dec; 45(12):3279-86. PubMed ID: 11709298
[TBL] [Abstract][Full Text] [Related]
16. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.
Chen Y; Delmas J; Sirot J; Shoichet B; Bonnet R
J Mol Biol; 2005 Apr; 348(2):349-62. PubMed ID: 15811373
[TBL] [Abstract][Full Text] [Related]
17. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
18. Screening in a spirit haunted world.
Shoichet BK
Drug Discov Today; 2006 Jul; 11(13-14):607-15. PubMed ID: 16793529
[TBL] [Abstract][Full Text] [Related]
19. Increased folding stability of TEM-1 beta-lactamase by in vitro selection.
Kather I; Jakob RP; Dobbek H; Schmid FX
J Mol Biol; 2008 Oct; 383(1):238-51. PubMed ID: 18706424
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of laboratory mutants of extended-spectrum beta-lactamase TEM-60.
Caporale B; Franceschini N; Perilli M; Segatore B; Rossolini GM; Amicosante G
Antimicrob Agents Chemother; 2004 Sep; 48(9):3579-82. PubMed ID: 15328132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
